ASPEN PHARMACAR/ADR (APNHY) Rating Increased to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of ASPEN PHARMACAR/ADR (OTCMKTS:APNHY) from a sell rating to a hold rating in a research note published on Monday, reports.

According to Zacks, “Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa. “

APNHY has been the subject of several other research reports. JPMorgan Chase & Co. downgraded shares of ASPEN PHARMACAR/ADR from an overweight rating to a neutral rating in a research report on Thursday, March 14th. ValuEngine downgraded shares of ASPEN PHARMACAR/ADR from a sell rating to a strong sell rating in a research report on Friday, February 15th.

Shares of OTCMKTS:APNHY opened at $7.27 on Monday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.05 and a quick ratio of 1.34. ASPEN PHARMACAR/ADR has a 52-week low of $6.01 and a 52-week high of $21.51. The company has a market capitalization of $3.46 billion, a price-to-earnings ratio of 5.82, a PEG ratio of 1.01 and a beta of 1.10.


Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty, branded, and generic pharmaceutical products worldwide. The company offers various oral solid dose, liquids, semi-solids, steriles, biogicals, active pharmaceutical ingredients, and infant nutritional products.

Featured Story: Momentum Indicators

Get a free copy of the Zacks research report on ASPEN PHARMACAR/ADR (APNHY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ASPEN PHARMACAR/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASPEN PHARMACAR/ADR and related companies with's FREE daily email newsletter.